Stereotactic body radiotherapy using a radiobiology‐based regimen for stage I nonsmall cell lung cancer

BACKGROUND: The most common regimen of stereotactic body radiotherapy (SBRT) for stage I nonsmall cell lung cancer in Japan is 48 grays (Gy) in 4 fractions over 4 days. Radiobiologically, however, higher doses are necessary to control larger tumors, and interfraction intervals should be >24 hours...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2012-04, Vol.118 (8), p.2078-2084
Hauptverfasser: Shibamoto, Yuta, Hashizume, Chisa, Baba, Fumiya, Ayakawa, Shiho, Manabe, Yoshihiko, Nagai, Aiko, Miyakawa, Akifumi, Murai, Taro, Iwata, Hiromitsu, Mori, Yoshimasa, Mimura, Mikio, Ishikura, Satoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND: The most common regimen of stereotactic body radiotherapy (SBRT) for stage I nonsmall cell lung cancer in Japan is 48 grays (Gy) in 4 fractions over 4 days. Radiobiologically, however, higher doses are necessary to control larger tumors, and interfraction intervals should be >24 hours to take advantage of reoxygenation. In this study, the authors tested the following regimen: For tumors that measured 3.0 cm in greatest dimension, radiation doses of 44 Gy, 48 Gy, and 52 Gy, respectively, were given in 4 fractions with interfraction intervals of ≥3 days. METHODS: Among 180 patients with histologically proven disease who entered the study, 120 were medically inoperable, and 60 were operable. The median patient age was 77 years (range, 29‐92 years). SBRT was performed with 6‐megavolt photons using 4 noncoplanar beams and 3 coplanar beams. Isocenter doses of 44 Gy, 48 Gy, and 52 Gy were received by 4 patients, 124 patients, and 52 patients, respectively. RESULTS: The overall survival rate for all 180 patients was 69% at 3 years and 52% at 5 years. The 3‐year survival rate was 74% for operable patients and 59% for medically inoperable patients (P = .080). The 3‐year local control rate was 86% for tumors ≤3 cm (44/48 Gy) and 73% for tumors >3 cm (52 Gy; P = .050). Grade ≥2 radiation pneumonitis developed in 13% of patients (10% of the 44‐Gy/48‐Gy group and 21% of the 52‐Gy group; P = .056). All other grade 2 toxicities developed in
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.26470